HanX Biopharmaceuticals is gearing up to begin a Phase I/II trial in relapsed/refractory lymphoma after gaining a regulatory nod from the US Food and Drug Administration (FDA).
The planned Phase I/II trial of HX-009 will mark the first US-based study of HanX’s antibody. The Wuhan-China based biotech has previously studied the drug in China and Australia.
Go deeper with GlobalData
HX-009 is a bispecific antibody targeting both integrin-associated protein CD47 and programmed cell death protein 1 (PD-1). While trials testing checkpoint inhibitors targeting PD-1 have been gaining steam, there is still significant unmet patient need in the oncology space. Meanwhile, pharma is also moving to develop chimeric antigen receptor T- cell (CAR-T) therapies for lymphoma.
Drug development in the US and China
The planned Phase I/II trial of HX-009 will expand the global footprint of HanX as it pursues clinical development in the US. This follows a trend of more domestic Chinese companies developing checkpoint inhibitors, potentially diminishing revenue for Western pharma companies.
Meanwhile, China is rapidly becoming a major player in the global pharmaceutical market, with development programs ranging from CAR-T cell therapies to small molecules for rare diseases. In 2022, China accounted for 27.7% of global clinical trial activity—representing a sharp uptick from its previous 10-year average, according to GlobalData.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
